TY  - CHAP
M1  - Book, Section
TI  - Systemic Sarcoidosis
A1  - Moller, David R.
A1  - Chen, Edward S.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Sarcoidosis  is  a  multisystem  disorder  characterized  by  noncaseating  granulomatous  inflammation  at  sites  of  disease.1  Although  any  organ  can  be  involved,  the  disease  most  commonly  affects  the  lungs  and  intrathoracic  lymph  nodes.  A  diagnosis  of  sarcoidosis  is  most  securely  established  from  compatible  clinical  and  radiologic  findings,  confirmed  by  a  biopsy  showing  noncaseating  epithelioid  granulomas  in  more  than  one  organ  and  the  exclusion  of  granulomatous  disorders  of  known  cause.  Clinical,  epidemiologic,  and  family  studies  support  the  hypothesis  that  sarcoidosis  is  triggered  by  exposure  to  microbial  agents  in  individuals  with  a  genetic  susceptibility  to  the  disease.  The  clinical  course  is  highly  variable,  with  a  mortality  rate  of  <1%  to  5%.  Corticosteroids  remain  the  mainstay  of  treatment  for  patients  with  threatened  organ  failure  or  progressive  disease.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122360628
ER  -